Argentina has been developing its cannabis production chain in recent years, promoting medical and scientific research on the medicinal use of the plant and its derivatives, as well as its industrial use. Pampa Hemp has recently been able to develop and produce the first medical cannabis seed in Argentina. The news will benefit the whole cannabis industry in the country.

Pampa Hemp, an Argentinean SME dedicated to the research, development, and production of cannabis for medicinal purposes, announces a historic achievement in the country with the approval of its first native cannabis seed variety, PH LOBERA, by the National Seed Institute (INASE).

Read more about Pampa Hemp and find the latest cannabis news with the Hemp.im mobile app.

This scientific breakthrough achieved by Pampa Hemp is important for the entire cannabis industry, as it eliminates the need to import seeds

After more than several years of research and development work, this new seed variety has been approved and is now part of Argentina’s National Cultivar Registry. Authorized local producers and people registered in the Reprocann (National Registry of Patients in Treatment with Cannabis) can now acquire the seed and obtain better results thanks to its ability to better adapt to the climatic conditions of the region. In addition, this scientific breakthrough is important for the entire cannabis industry, as it eliminates the need to import seeds.

“Our goal was to create a variety that has excellent adaptation to the soil, climate, and resistance to the pests that exist in the Province of Buenos Aires for outdoor cannabis crops. It also has a high concentration of THC and CBG, the latter a cannabinoid that is not so easy to find and is being increasingly observed for the therapeutic benefits it offers as an anti-inflammatory and pain reliever. We are currently working on genotyping tasks and molecular markers that will allow us to continue with the photo-improvement work,” explained Sebastian Tedesco, Technical Director and Co-Founder of Pampa Hemp.

This development began as an idea in 2017, with different tests being carried out by Pampa Hemp in a field in Lobos with various seed varieties to find the one that would best adapt to the soil and coexist better with native plant species. This process was the kick that led to the creation of a new strain that is now available on the market.

The registration of PH LOBERA in the registry is one more step towards the consolidation of the cannabis sector in Argentina, which seeks to promote medical and scientific research, as well as the industrial development of the crop. The official recognition of this strain will contribute to the growth of the cannabis production chain and to the strengthening of Argentina’s position in the global market of hemp and cannabis products.

TORONTO–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), is pleased to announce that it has received a purchase order from a Brazilian pharmaceutical CBD product importation and distribution company, to supply finished CBD products for wholesale distribution that have already received approval for sale in Brazil. These products are among the first products of their kind to be approved by the Brazil Health Authority (ANVISA) and will ship upon approval by Health Canada.

“This is just a starting point for Heritage in Brazil as we are in the process of establishing a long-term supply agreement for CBD products which will also include access to our entire THC product portfolio once medical use cannabis becomes fully legalized in Brazil.”

Tweet this

In 2021, Health Canada granted Heritage with a license to export cannabis products from Canada to Brazil. This will mark the first full shipment of products following the prior successful shipment to Brazil made by Heritage for the testing phase with ANVISA.

“We are very pleased to be in a position to expand our products and brands on a global scale, and to be working with a well recognized partner and their large distribution network in Brazil,” said David Schwede, CEO of Heritage. “This is just a starting point for Heritage in Brazil as we are in the process of establishing a long-term supply agreement for CBD products which will also include access to our entire THC product portfolio once medical use cannabis becomes fully legalized in Brazil.”

About Heritage Cannabis Holdings Corp.

Heritage Cannabis is a leading cannabis company offering innovative products to both the medical and recreational legal cannabis markets in Canada and the U.S., operating under two licensed manufacturing facilities in Canada. The company has an extensive portfolio of high-quality cannabis products under the brands Purefarma, Pura Vida, RAD, Premium 5, Thrifty, feelgood., the CB4 suite of medical products in Canada and ArthroCBD in the U.S.

ON BEHALF OF THE BOARD OF DIRECTORS OF HERITAGE CANNABIS HOLDINGS CORP.

“David Schwede”
David Schwede, CEO

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

CALGARY, AB / ACCESSWIRE / March 30, 2023 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it has signed a Supply Agreement with Israeli company Y.S.A Holdings (“YSA”). The business arrangement sets forth a supply agreement between the two companies.

Under the terms of the agreement, CannaPharmaRx will cultivate commercial cannabis at its Facility in Canada and supply YSA Group material for the sole purpose of selling finished product in Israel and Morocco. The agreement shall initially be for 24 months and automatically renews for periods of 24 months each.

YSA will buy from CannaPharmaRX a minimum of 400kg of Material per annum per each country comprising the Territory during the Term. It is anticipated that purchase orders will be between 400kg and 1000kg and occur as often as four times annually. Deliveries are anticipated to begin in Q3 quarter. Anticipated Revenues can be between $6 – $15 million on a yearly basis depending on quantity and timing.

“In accordance with the company’s model, we are building an international brand for our product. For this agreement, the brand will contain up to fifteen strains from the large pool of CannapharmaRX’s exclusive inventory. This is an important agreement for us as YSA’s CEO has significant experience in this industry and specifically in the international marketplace. Until recently he was the CEO of Teva Adir, one of the original and leading cannabis companies in Israel and currently advises the Moroccan government on the regulation issues required to market cannabis in the field. We continue to grow our customers and distribution across the globe,” stated Nick Colvin, CEO of CannaPharmaRx.

About CannapharmaRx, Inc.

CannapharmaRx is focused on the acquisition and development of state-of-the-art cannabis grow facilities in Canada. CPMD is in discussion with other companies regarding potential acquisitions. CannapharmaRx’s business strategy is to become a leader in high quality and low-cost production of cannabis through the development, acquisition, and enhancement of existing facilities. CannapharmaRx is committed to operating high-quality facilities utilizing the latest technology in combined heat and power generation to ensure being a low-cost producer of cannabis.

Safe Harbor Statement

Cautionary Note Regarding Forward-Looking Information or Statements

This press release contains forward-looking information or statements. All statements that are or information which is not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance, are ‘forward-looking information or statements.’ Forward-looking information or statements can be identified by the use of words such as ‘plans,’ ‘expects,’ or ‘does not expect,’ ‘is expected,’ ‘estimates,’ ‘intends,’ ‘anticipates,’ or ‘does not anticipate,’ or ‘believes,’ or variations of such words and phrases or statements that certain actions, events or results ‘may,’ ‘could,’ ‘would,’ ‘might’ or ‘will’ be taken, occur or be achieved. With respect to forward-looking information and statements contained herein, Management of CannapharmaRx has made numerous assumptions, including, among other things, assumptions about general business and economic conditions. Such forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from any future results, events, or developments expressed or implied by such forward-looking information or statements. Readers are cautioned not to place undue reliance on such forward-looking information or statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking information or statements. CannapharmaRx assumes no obligation to update any forward-looking information or statements, even if new information becomes available as a result of future events, new information, or for any other reason except as required by law.